Why CMC readiness is becoming central to biopharma licensing deals
As licensing expands, manufacturing evidence is becoming a decisive test of asset value and deal confidence.
Sponsored
Formulation as a key differentiator in crowded therapeutic areas
Asia’s clinical research revolution: Why the world’s innovation centre is shifting east
Reaching maturity: A roadmap for Quality Excellence amid regulatory transformation
Why your manufacturing floor is your greatest compliance risk – and opportunity
Commercialising drugs in Europe: Lean models for first-time launchers
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
Why manual aseptic filling often provides faster start dates than automated lines
